A Study on Adverse Drug Reaction Profile of 2nd Line Drugs in Multi Drug Resistant (MDR) and Extensively Drug Resistant (XDR) Tuberculosis Cases Registered under DR-TB Centre in a Tertiary Care Hospital.

Report WHO/HTM/TB/2006.375 (World Health Organization, Geneva, 2006), Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006;55:1176.              

World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2014.

Mahadev B, Kumar P, Agarwal SP, et al. Surveillance of drug resistance to anti-tuberculosis drugs in districts of Hoogli in West Bengal and Mayurbhanj in Orissa. Indian J Tuberc 2005;52:5-10. http://www.imsear.li.mahidol.ac.th/handle/123456789/146942.             

Paramasivan CN, Venkataraman P, Chandrasekaran V, et al. Surveillance of drug resistance in tuberculosis in two districts of South India. Int J Tuberc Lung Dis 2002;6(6):479-84.                     

Technical and Operational Guidelines for TB Control in India 2016. https://tbcindia.gov.in/index1.php?lang=1&level=2&sublinkid=4573&lid=3177

Patel SV, Bhikhubhai NK, Patel AB, et al. Adverse drug reactions in patients put on Multi Drug Resistant Tuberculosis (MDR-TB) treatment in seven districts of central Gujarat. Jour Young Pharmacists 2015;7(4):425-31.

Hire R, Kale AS, Dakhale GN, et al. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India. Mediterr J Hematol Infect Dis 2014;6(1):e2014061.            

Dela AI, Tank NKD, Singh AP, et al. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study. Lung India 2017;34(6):522-6.             

Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004;8(11):1382-4.